Table 2 Serial changes of the platelets, coagulation and fibrinolytic markers in blood

From: Antithrombotic effects of losartan in patients with hypertension complicated by atrial fibrillation: 4A (Angiotensin II Antagonist of platelet Aggregation in patients with Atrial fibrillation), a pilot study

Parameters

0w

8w

12w

P-value (0w vs. 8w)

P-value (0w vs. 12W)

TF (ng ml−1), mean (s.d.)

14.2 (3.6)

12.9 (3.5)

10.9 (4.5)

0.5438

0.0299

vWF (%), mean (s.d.)

170.3 (51.6)

166.9 (41.7)

177.4 (45.1)

0.9702

0.8806

PAI-1 (IU ml−1), mean (s.d.)

11.7 (3.6)

12.3 (3.6)

8.5 (3.1)

0.8442

0.0122

Soluble P-selectin (ng ml−1), mean (s.d.)

72.1 (20.7)

55.2 (20.0)

48.4 (34.4)

0.1054

0.0145

SPA peak (%), mean (s.d.)

100.0 (0)

70.9 (53.4)

57.2 (41.5)

0.0711

0.0040

SPA AUC (%), mean (s.d.)

100.0 (0)

78.7 (48.0)

42.8 (33.4)

0.0947

<0.0001

CD62P (+) platelets (%), mean (s.d.)

5.8 (4.6)

3.4 (2.1)

2.8 (2.1)

0.0461

0.0122

  1. Abbreviations: AUC, area under the curve; CD 62P (+), CD62P positive; PAI-1, type 1 plasminogen activator inhibitor; SPA, small platelet aggregates; TF, tissue factor; vWF, von Willebrand factor; W, week.
Back to article page